Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

• Published in: Oncoimmunology Vol. 7; no. 1; p. e1377872
• Main Authors: Tsuchiya, Nobuhiro, Hosono, Ako, Yoshikawa, Toshiaki, Shoda, Kayoko, Nosaka, Kazuto, Shimomura, Manami, Hara, Junichi, Nitani, Chika, Manabe, Atsushi, Yoshihara, Hiroki, Hosoya, Yosuke, Kaneda, Hide, Kinoshita, Yoshiaki, Kohashi, Kenichi, Yoshimura, Kenichi, Fujinami, Norihiro, Saito, Keigo, Mizuno, Shoichi, Nakatsura, Tetsuya
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02.01.2018; Taylor & Francis Group
• Subjects: CTL; glypican-3 (GPC3); Original Research; pediatric solid tumors; peptide vaccine; phase I; pediatric solid tumors; CTL; phase I; peptide vaccine; glypican-3 (GPC3)

The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3-peptide vaccination in patients with pediatric solid tum...